Renal and CVRM Biomarkers: No longer just scientific tools, but strategic accelerators
By Caidya
In renal and cardiovascular-renal-metabolic drug development, biomarkers are no longer simply supportive or exploratory readouts, they are now decision-shaping insights. In this whitepaper, Caidya discusses the secondary benefits that biomarkers bring to drug development, from enabling personalized medicine to smaller trials, with earlier safety assessments, and more. Download now to understand how to apply biomarkers thoughtfully and correctly in order to support decisions, not just understanding.